Skip to main content
OpenTrials
Completed

NCT Number: NCT01813383

Clinical Relevance of Typing HLA-DR7-DQ2

Celiac disease patients with HLA-DR7-DQ2 haplotype have the same histological, analytical and clinical behaviour as patients with HLA-DR3-DQ2 haplotype.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Celiac Disease Patients Following Recommendations of ESPGHAN Celiac Disease Digestive System Diseases Gastrointestinal Diseases HLA-DQ2 Typing Include HLA-DR7-DQ2 Haplotypes Intestinal Diseases Malabsorption Syndromes Metabolic Diseases Nutritional and Metabolic Diseases

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Corporació Sanitària i Universitària Parc Taulí

Sabadell, Barcelona, 08208, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of celiac disease following ESPGHAN recommendations
  • HLA-DQ2 typing including HLA-DR3-DQ2 and HLA-DR7-DQ2 haplotypes

Exclusion criteria

  • Patients who have not been diagnosed for celiac disease
  • HLA-DQ2 typing that not include HLA-DR7-DQ2 haplotype

Treatment and study plan

There is not any intervention

Other

Primary outcomes

  1. Anti-tissue transglutaminase

    Time frame: Up to 1 month after diagnosis

Secondary outcomes

  1. Anti-Endomysium autoantibodies

    Time frame: Up to 1 month after diagnosis

Other outcomes

  1. Oberhuber histological damage classification

    Time frame: Up to 1 month after diagnosis

  2. Clinical characteristics of celiac disease

    Time frame: Up to 1 month after diagnosis

    Asymptomatic, intestinal symptoms, extra-intestinal symptoms, European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) score

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Corporacion Parc Tauli

Other

Registry information

Acronym: HLA

Important dates

Study start
2010
Primary completion
2012
Study completion
2013
First posted
Mar 19, 2013
Registry last updated
Mar 19, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.